Aptevo Therapeutics Announces $8 Million At-the-Market Offering Under Nasdaq Rules
Reuters
Jun 18
Aptevo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces $8 Million At-the-Market Offering Under Nasdaq Rules
Aptevo Therapeutics Inc., a clinical-stage biotechnology company specializing in immune-oncology therapeutics, has announced an $8 million offering priced at-the-market under Nasdaq rules. The company has entered into securities purchase agreements with healthcare-focused and institutional investors to purchase 2,465,000 shares of its common stock or pre-funded warrants, along with warrants to buy up to 12,325,000 additional shares. Each share is priced at $3.25 and comes with five warrants for additional shares at the same price, exercisable upon stockholder approval and expiring five years afterward. The offering is expected to close shortly, with Roth Capital Partners serving as the placement agent. Aptevo plans to utilize the net proceeds for clinical development, working capital, and general corporate needs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040895) on June 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.